摘要
目的探讨MRP1、ToPo-Ⅱ在非小细胞肺癌(NSCLC)中的表达及其临床意义。方法采用免疫组织化学法检测117例NSCLC,26例对照组断端支气管黏膜中MRP1、ToPo-Ⅱ的表达水平。结果 (1)MRP1在NSCLC阳性表达高于对照组(P<0.05),与组织类型、分期、淋巴结转移有关(P<0.05);MRP1在鳞癌中的表达低于腺癌(P<0.05);随分期增高,淋巴结转移表达增强;MRP1表达与性别、年龄、分化无关(P>0.05)。(2)ToPo-Ⅱ表达在NSCLC组高于对照组(P<0.05);与组织类型、分化有关(P<0.05);鳞癌ToPo-Ⅱ表达高于腺癌;随分化程度降低表达增强(P<0.05);ToPo-Ⅱ与性别、年龄、分期、淋巴结转移无关(P>0.05)。(3)MRP1与ToPo-Ⅱ呈负相关(r=-0.269,P<0.05)。结论 NSCLC存在MRP1及ToPo-Ⅱ的高表达,两者可能参与肿瘤进展。
Objective To investigate the expression and clinical significance of multidrug resistance associated protein-1 and DNA topoisomerase-Ⅱ. Methods MRP1 and ToPo-Ⅱ were measured in 117 samples of non-small cell lung cancer tissues by immunohistochemistry two-step method using monoclonal antibody to their protein. Results The positive expression of MRP1 was higher than that in sectional bronchial mucosa （P〈0.05）;MRP1 expression in adenocarcinoma （Ad） was significantly higher than that in squamous carcinoma （P〈0.05）; The positive expression of MRP1 in Ⅲ stage group was higher than that in I stage group （P〈0.05）;MRP1 expression correlated significantly with lymph node metastasis; But the positive rate of the expression of MRP1 had no significantly different between the different degrees of cell differentiation （P〉0.05）. The positive rate of ToPo-Ⅱ was significantly higher in the group of the squamous cell carcinomas than that in that of the adenocarcinoma （P〈0.05）; ToP o-Ⅱexpression in the poorly differentiated group was higher than one in highly differentiated group; The positive rates of ToPo-Ⅱ was not correlated with TMN stage and lymph node metastasis. ToPo-Ⅱexpression correlated with MRP1（r=-0.269, P〈0.05）. Conclusion The coexpression of MRP1 and ToPo-Ⅱ could be involved in the advanced NSCLC .
出处
《中华临床医师杂志（电子版）》
CAS
2014年第18期31-35,共5页
Chinese Journal of Clinicians(Electronic Edition)
基金
内蒙古自治区高等学校科学研究项目(NJZY12146)
内蒙古自治区科学基金资助项目(2009MS1119)
